Comparative Pharmacology
Head-to-head clinical analysis: DACOGEN versus VIDAZA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DACOGEN versus VIDAZA.
DACOGEN vs VIDAZA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Decitabine is a hypomethylating agent that incorporates into DNA and inhibits DNA methyltransferase, resulting in hypomethylation of DNA and subsequent gene reactivation.
Azacitidine is a pyrimidine nucleoside analog of cytidine that inhibits DNA methyltransferase, causing hypomethylation of DNA and direct cytotoxicity in abnormal hematopoietic cells.
15 mg/m² intravenously over 3 hours every 8 hours for 3 consecutive days, repeated every 6 weeks for a minimum of 4 cycles.
75 mg/m2 subcutaneously or intravenously once daily for 7 days every 4 weeks.
None Documented
None Documented
Terminal elimination half-life: approximately 1.5 hours at steady state. Short half-life necessitates daily administration in current regimens.
Terminal half-life: 5-7 hours (subcutaneous); 3-5 hours (intravenous); supports 7-day dosing cycle
Renal excretion of unchanged drug and metabolites: approximately 90% of total clearance. Biliary/fecal excretion: <10%.
Renal: 50-85% as unchanged drug and metabolites; biliary/fecal: minimal (<10%)
Category C
Category C
Hypomethylating Agent
Hypomethylating Agent